External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study.
Caroline M van der Starre, Chris H Bangma, Maarten J Bijlsma...
https://pubmed.ncbi.nlm.nih.gov/39871169/Actively Recruiting
Led by Comprehensive Cancer Centre The Netherlands · Updated on 2026-05-22
837
Participants Needed
28
Research Sites
39 weeks
Total Duration
Researchers are comparing robot-assisted radical prostatectomy RARP and external beam radiotherapy EBRT, sometimes combined with androgen deprivation therapy ADT, for men with high-risk non-metastatic prostate cancer. The study aims to understand differences in quality of life, functional outcomes, cost-effectiveness, progression-free survival, and distant metastasis-free survival. There is currently no clear consensus on which treatment is better, leading to variation in hospital practices. Participants will receive either RARP, which may include pelvic lymph node dissection and possibly adjuvant radiotherapy or androgen deprivation therapy, or EBRT delivered at an effective radiation dose, possibly combined with a brachytherapy boost and pelvic lymph node dissection. Positive lymph node findings will not exclude participants and may be treated with lymph node irradiation. Treatment details vary based on clinical decisions. During the study, participants will be followed for up to five years, with key assessments at three years including health-related quality of life and functional outcomes. Cost-effectiveness will also be evaluated at three years, while progression-free and distant metastasis-free survival will be tracked up to five years. The study involves regular monitoring to gather these outcomes and support shared decision-making for future patients.
CONDITIONS
High-Risk prostatE Cancer radiatiOn Versus surgERy
B
Berdine Heesterman, MD, PhD
C
Caroline van der Starre, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Comprehensive Cancer Centre The Netherlands
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years after diagnosis
Participants who undergo routine care are observed to compare outcomes between different treatment options for high-risk prostate cancer.
Periodic visits as part of routine healthcare
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Caroline M van der Starre, Chris H Bangma, Maarten J Bijlsma...
https://pubmed.ncbi.nlm.nih.gov/39871169/Comprehensive Cancer Centre The Netherlands
Lead Sponsor